⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733962 | 0.88 | CASP2 (0.40) | — | |
| SCHEMBL3550215 | 0.86 | CASP2 (0.61) | — | |
| SCHEMBL3996566 | 0.86 | SLC6A5 (0.56) | — | |
| SCHEMBL3351989 | 0.85 | CASP2 (0.56) | — | |
| SCHEMBL13614252 | 0.85 | SLC6A5 (0.63) | — | |
| SCHEMBL7700850 | 0.85 | CASP2 (0.70) | — | |
| SCHEMBL2031148 | 0.83 | — | — | |
| SCHEMBL24412649 | 0.83 | CASP2 (0.74) | — | |
| SCHEMBL11739321 | 0.83 | CASP2 (0.74) | — | |
| SCHEMBL25066831 | 0.83 | CASP2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122764-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009042922-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-0137145-B1 | NEW CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1988-04-27 | — | — | EP | disclosed |